These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

456 related items for PubMed ID: 19647953

  • 21. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience.
    Mazzarotto R, Boso C, Vianello F, Aversa MS, Chiarion-Sileni V, Trentin L, Zambello R, Muzzio PC, Fiore D, Sotti G.
    Int J Radiat Oncol Biol Phys; 2007 Jul 01; 68(3):823-9. PubMed ID: 17379431
    [Abstract] [Full Text] [Related]

  • 22. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 23. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y.
    Eur J Haematol; 2008 Dec 01; 81(6):448-53. PubMed ID: 18691256
    [Abstract] [Full Text] [Related]

  • 24. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma.
    Kamezaki K, Kikushige Y, Numata A, Miyamoto T, Takase K, Henzan H, Aoki K, Kato K, Nonami A, Kamimura T, Arima F, Takenaka K, Harada N, Fukuda T, Hayashi S, Ohno Y, Eto T, Harada M, Nagafuji K.
    Bone Marrow Transplant; 2007 May 01; 39(9):523-7. PubMed ID: 17369863
    [Abstract] [Full Text] [Related]

  • 25. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.
    Hoppe BS, Moskowitz CH, Filippa DA, Moskowitz CS, Kewalramani T, Zelenetz AD, Yahalom J.
    J Clin Oncol; 2008 Apr 10; 26(11):1858-64. PubMed ID: 18332466
    [Abstract] [Full Text] [Related]

  • 26. Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma.
    Tsirigotis P, Dray L, Resnick IB, Ackerstein A, Gesundheit B, Elad S, Or R, Shapira MY.
    Ann Hematol; 2010 Mar 10; 89(3):263-72. PubMed ID: 19693502
    [Abstract] [Full Text] [Related]

  • 27. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
    Park YH, Sohn SK, Kim JG, Lee MH, Song HS, Kim MK, Jung JS, Lee JJ, Kim HJ, Kim DH.
    Clin Cancer Res; 2009 Mar 15; 15(6):2107-15. PubMed ID: 19276283
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.
    Cairoli R, Grillo G, Tedeschi A, Gargantini L, Marenco P, Tresoldi E, Barbarano L, Nosari AM, Morra E.
    Bone Marrow Transplant; 2002 Mar 15; 29(6):473-7. PubMed ID: 11960265
    [Abstract] [Full Text] [Related]

  • 29. [Efficacy of CHOP+/-Rituximab-like therapy plus radiation therapy for patients with diffuse large B-cell lymphoma stage I].
    Ueda K, Yokoyama M, Asai H, Koudaira M, Yamada S, Katsube A, Mishima Y, Sakajiri S, Takeuchi K, Saotome T, Terui Y, Takahashi S, Hatake K.
    Gan To Kagaku Ryoho; 2010 May 15; 37(5):853-7. PubMed ID: 20495315
    [Abstract] [Full Text] [Related]

  • 30. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, Wang X, Jiang K, Nastoupil LJ, Khan MK.
    Int J Radiat Oncol Biol Phys; 2013 Jul 01; 86(3):569-77. PubMed ID: 23540349
    [Abstract] [Full Text] [Related]

  • 31. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
    Goto N, Tsurumi H, Kasahara S, Kanemura N, Hara T, Yasuda I, Shimizu M, Murakami N, Sawada M, Yamada T, Takemura M, Seishima M, Kito Y, Takami T, Moriwaki H.
    Eur J Haematol; 2011 Sep 01; 87(3):217-27. PubMed ID: 21575062
    [Abstract] [Full Text] [Related]

  • 32. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
    Hess G, Flohr T, Huber C, Kolbe K, Derigs HG, Fischer T.
    Bone Marrow Transplant; 2003 May 01; 31(9):775-82. PubMed ID: 12732884
    [Abstract] [Full Text] [Related]

  • 33. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T, Raida L, Faber E, Vondrakova J, Prochazka V, Kubova Z, Skoumalova I, Jarosova M, M LK, Paucek B, Myslivecek M, Neoral C, Oral I, Jarkovsky J, Dusek L, Indrak K.
    Neoplasma; 2008 May 01; 55(3):215-21. PubMed ID: 18348654
    [Abstract] [Full Text] [Related]

  • 34. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
    Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM.
    Ann Rheum Dis; 2006 Aug 01; 65(8):1033-7. PubMed ID: 16322082
    [Abstract] [Full Text] [Related]

  • 35. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC, Best JH.
    Cancer; 2005 Apr 15; 103(8):1644-51. PubMed ID: 15756658
    [Abstract] [Full Text] [Related]

  • 36. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
    Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D.
    J Clin Oncol; 2006 Sep 01; 24(25):4123-8. PubMed ID: 16896005
    [Abstract] [Full Text] [Related]

  • 37. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H, Reinke P, Neuhaus R, Lehmkuhl H, Oertel S, Atta J, Planker M, Gärtner B, Lenze D, Anagnostopoulos I, Riess H, Trappe RU.
    Cancer; 2012 Oct 01; 118(19):4715-24. PubMed ID: 22392525
    [Abstract] [Full Text] [Related]

  • 38. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.
    Bone Marrow Transplant; 2000 Aug 01; 26(4):383-8. PubMed ID: 10982284
    [Abstract] [Full Text] [Related]

  • 39. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E, MabThera International Trial (MInT) Group.
    Lancet Oncol; 2008 May 01; 9(5):435-44. PubMed ID: 18400558
    [Abstract] [Full Text] [Related]

  • 40. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS.
    J Clin Oncol; 2010 Sep 20; 28(27):4170-6. PubMed ID: 20713859
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.